MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$51,550K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Prepaid expenses, operating leas...
    • Share-based compensation
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses, tax liability ...
    • Accounts payable
    • Net accretion of discounts/premi...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
43,665
-8,278
-5,852
16,016
Depreciation and amortization
2
3
3
35
Loss on disposal of assets
-18
-
-
-
Net accretion of discounts/premiums on debt securities
-5
-51
-97
-113
Share-based compensation
424
613
774
1,047
Gain on sale of joint venture
-
-
0
22,350
Loss on investment in joint venture
0
0
0
0
Prepaid expenses, operating lease right-of-use assets and other current assets
-2,443
155
-815
773
Accounts payable
-107
814
-143
150
Accrued expenses, tax liability and operating lease liabilities
-521
-712
33
-350
Deferred revenue
0
-212
-212
-212
Net cash provided by (used in) operating activities
45,919
-7,978
-4,679
-6,550
Purchases of marketable securities
0
0
7,075
738
Proceeds from maturities of marketable securities
5,500
17,900
11,000
9,965
Proceeds from sale of common stock received from sale of joint venture
-
-
0
20,000
Investment in joint venture
0
0
0
0
Net cash provided by investing activities
5,500
17,900
3,925
29,227
Proceeds from the issuance of common stock from exercise of stock options
-
3
0
0
Proceeds from the issuance of common stock under the stock purchase plan
13
-
6
10
Payments of offering costs
-
-
0
0
Proceeds from the issuance of common stock from exercise of stock options
121
-
-
-
Net cash provided by financing activities
131
3
6
0
Net increase (decrease) in cash and cash equivalents
51,550
9,925
-748
22,677
Cash and cash equivalents beginning of period
41,299
31,374
32,122
13,903
Cash and cash equivalents end of period
92,849
41,299
31,374
32,122
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net income (loss)$43,665K (328.11%↑ Y/Y)Prepaid expenses,operating lease...-$2,443K (-217.17%↓ Y/Y)Proceeds from maturitiesof marketable...$5,500K (-78.43%↓ Y/Y)Proceeds from theissuance of common stock...$121K Proceeds from theissuance of common stock...$13K (30.00%↑ Y/Y)Share-based compensation$424K (-87.86%↓ Y/Y)Loss on disposal ofassets-$18K Depreciation andamortization$2K (-96.30%↓ Y/Y)Net cash provided by(used in) operating...$45,919K (347.09%↑ Y/Y)Net cash provided byinvesting activities$5,500K (-61.04%↓ Y/Y)Net cash provided byfinancing activities$131K (1210.00%↑ Y/Y)Canceled cashflow$633K Net increase(decrease) in cash and cash...$51,550K (1256.35%↑ Y/Y)Accrued expenses, taxliability and operating...-$521K (37.38%↑ Y/Y)Accounts payable-$107K (32.70%↑ Y/Y)Net accretion ofdiscounts/premiums on debt...-$5K (98.62%↑ Y/Y)

Rallybio Corp (RLYB)

Rallybio Corp (RLYB)